Adding an international twist to the year's biggest patent story, Myriad has surrendered its BRCA patents in Australia, reports Genomics Law Report's Dan Vorhaus and John Conley. Several months ago, a group of plaintiffs in Australia filed a lawsuit against Myriad similar to the one filed in the US, arguing that the patents are invalid because genes can't be patented.